Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Over the past 4 years, Amneal Pharmaceuticals, Inc. Class A Common Stock has achieved a revenue compound annual growth rate (CAGR) of 8.8%.
Historical revenue and profitability trends for Amneal Pharmaceuticals, Inc. Class A Common Stock
The chart above illustrates Amneal Pharmaceuticals, Inc. Class A Common Stock's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Amneal Pharmaceuticals, Inc. Class A Common Stock's business.
How efficiently Amneal Pharmaceuticals, Inc. Class A Common Stock converts revenue into profit
Profit margins reveal how much of each dollar of revenue Amneal Pharmaceuticals, Inc. Class A Common Stock retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Amneal Pharmaceuticals, Inc. Class A Common Stock to continue growing earnings in the coming year. The consensus analyst rating is 4.25 based on 4 analysts.
Based on our comprehensive analysis, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Amneal Pharmaceuticals, Inc. Class A Common Stock's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Amneal Pharmaceuticals, Inc. Class A Common Stock stacks up against similar companies
Explore growth analysis for top stocks
Related: AMRX Valuation, AMRX Dividend, AMRX Financial Health
Compare: AMRX vs AAPL, AMRX vs MSFT, AMRX vs GOOGL